Table 2.

AEs Occurring in the Placebo Group and the Mangafodipir Group, According to NCI-CTCAE Version 3 or Sanofi-NCI Criteria (No Effect = 0, Mild = 1, Moderate = 2, Severe = 3 and Life Threatening = 4).

AE	Placebo (Seven Patients; 18 Cycles)				Mangafodipir (Seven Patients; 20 Cycles)
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 1	Grade 2	Grade 3	Grade 4
Neutropenia	3	1	1	1	4	1*	0	0
Other hematologic toxicity	15	1	0	0	13	0	0	0
Neurosensory toxicity	9	0	1	0	9	0	0	0
Oral mucositis	2	2	0	0	0	0	0	0
Nausea	7	3	0	0	9	1*	0	0
Vomiting	1	1	1	0	2	0	0	0
Diarrhea	0	0	0	0	8	0	0	0
Fatigue	4	2	0	0	4	0	0	0
Other AE	3†,‡,§	1¶	1#	0	1**	0	0	0
∑AE	44	11	4	1	50	2	0	0

^*Patient received a 10% higher dose during the first FOLFOX6 cycle.

^†Chest wall pain.

^‡Dyspnea.

^§Skin reaction (face).

^¶Pain in lower extremities.

^#Ileus.

^**Nasal mucositis.